Dergiler / The Journal of Breast Health / 2017 / Cilt: 13 - Sayı: 2

Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine

Sayfa
50–53
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

And, they can contribute to a more personalized management of breast cancer patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Breast cancer management changed from radical mastectomy to precision medicine in a period longer than a century. fte aims of these changes were to refrain from overdiagnoses and overtreatments as well as their harmful side effects and extra costs.
📊
Temel Bulgular & Veri:We now increasingly realise that a one-size-fits-all strategy does not apply to all breast cancer patients.
💡
Sonuç & Katkı:And, they can contribute to a more personalized management of breast cancer patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Breast cancer management changed from radical mastectomy to precision medicine in a period longer than a century. fte aims of these changes were to refrain from overdiagnoses and overtreatments as well as their harmful side effects and extra costs. Breast cancer is a heterogeneous disease and characterized by many morphological, clinical and molecular features. We now increasingly realise that a one-size-fits-all strategy does not apply to all breast cancer patients. Personalized medicine may be used for breast cancer screening, diagnosis and treatment. Individualized screening can decrease the number of unnecessary mammograms, additional radiologic studies, breast biopsies and false positivity rates. However, additional 15 to 20 years are necessary to reach the results of prospective randomized trials comparing low-risk and normal-risk women. We also should wait for outcomes of risk-based screening trials. fte rates of overtreatment in patients with early-stage breast cancer have reached 40% in many studies. Personalized treatment has succeeded in reducing it substantially by using tumour genetic profiling and tumour receptors in early breast cancer patients. However, it has its limits and it is impossible to generalize it to all patients. New biomarkers and molecular classifications have also led to the development of novel therapies and treatment strategies. And, they can contribute to a more personalized management of breast cancer patients.

🔖

Bu Makaleye Atıf Yap

ÖZMEN, V. (2017). Paradigm Shift From Halstedian Radical Mastectomy to Personalized Medicine. The Journal of Breast Health, Cilt: 13 - Sayı: 2, 50–53. https://ajindex.com/articles/362638

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Halsted CP, Benson JR, Jatoi I. A historical account of breast cancer sur- gery: beware of local recurrence but be not radical. Future Oncol 2014
  2. (PMID: 25145433) [CrossRef] Sakorafas GH, Safioleas M. Breast cancer surgery: an historical narra- tive. Part II. 18th and 19th centuries. Eur J Cancer Care 2010
  3. (PMID: 19674073) [CrossRef] Fisher B, Fisher ER. Barrier function of lymph nodes. Cancer Science 1966
  4. (PMID: 5949244) Fisher B. Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980
  5. (PMID: 7008932) Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twen- ty-five-year follow-up of a randomized trial comparing radical mastec- tomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002
  6. [CrossRef] Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irra- diation for the treatment of invasive breast cancer. N Engl J Med 2002
  7. [CrossRef] Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. New Eng J Med 1981
  8. (PMID: 7015141) [CrossRef] Seigneurin A, Labarère J, François O, Exbrayat C, Dupouy M, Filippi M, Colonna M. Overdiagnosis and overtreatment associated with breast can- cer mammography screening: A simulation study with calibration to pop- ulation-based data. Breast 2016
  9. (PMID: 27240167) [CrossRef] Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003
  10. (PMID: 12678566) [CrossRef] Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, Massat N, Duffy S, Lynge E, Paci E
  11. EUROSCREEN Working Group. J Med Screen 2012
  12. 19 Suppl 1:14-25. (PMID: 22972807) [CrossRef] Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, D’Orsi C, Harvey JA, Hayes MK, Huynh PT, Jokich PM, Lee SJ, Lehman CD, Mankoff DA, Nepute JA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG. ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol 2016
  13. R45-R49. (PMID: 27814813) [CrossRef] Nel